New Zealand Blood Service

Next Generation Sequencing Solution

The New Zealand Blood and Organ Service is evaluating options to upgrade its Next Generation Sequencing (NGS) platform to address the growing demand for high-resolution human leucocyte antigen (HLA) typing and cell free DNA (cfDNA) based monitoring of transplant patients. This upgrade is essential to maintain compliance with international best practice, improve turnaround times, and reduce ambiguity in transplant-related testing.
The proposed solution must be CE/IVD certified and demonstrate proven use in clinical environments for HLA typing and cfDNA analysis.